iLeukon Receives FDA Clearance of IND Application for A Phase II Study of mRNA-based non-alpha IL-2 variant, ILKN421H, in Advanced Non-Small Cell Lung Cancer (NSCLC)

Leukon Therapeutics, Inc., a San Diego-based clinical-stage biotechnology company developing next-generation mRNA-based immunotherapies, today announced that the U.S. Food and Drug Administration (FDA ...

Cheongju Craft Biennale 2025, the Designer of a New World Built by Craft

The new world designed by Cheongju and built by crafts was both strong and beautiful. More than 400,000 people who stepped into this world were moved and awed and applauded the experience. The 60 days ...